(R)-2-(4-氯苯甲酰胺基)-3-(1,2-二氢-2-氧代-4-喹啉基)丙酸 | 111911-90-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: (R)-2-(4-氯苯甲酰胺基)-3-(1,2-二氢-2-氧代-4-喹啉基)丙酸
• 中文别名: 瑞巴米特；2-(4-氯苯甲酰氨基)-3-(1,2-二氢-2-氧代-4-喹啉基)丙酸；瑞巴派特；(R)-2-(4-氯苯甲酰氨基)-3-(1,2-二氢-2-氧代-4-喹啉基)丙酸；瑞巴匹特
• 英文名称: (+)-2-(4-chlorobenzoylamino)-3-<2(1H)-quinolinon-4-yl>propionic acid
• 英文别名: Rebamipide, (R)-；(2R)-2-[(4-chlorobenzoyl)amino]-3-(2-oxo-1H-quinolin-4-yl)propanoic acid
• CAS: 111911-90-1
• 化学式: C₁₉H₁₅ClN₂O₄
• 分子量: 370.792
• InChiKey: ALLWOAVDORUJLA-MRXNPFEDSA-N

物化性质

• 沸点：
  695.0±55.0 °C(Predicted)
• 密度：
  1.394

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  26
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  95.5
• 氢给体数：
  3
• 氢受体数：
  4

ADMET

代谢

(R)-(+)-雷巴米吡啶已知的人体代谢物包括8-羟基雷巴米吡啶和6-羟基雷巴米吡啶。

(R)-(+)-Rebamipide has known human metabolites that include 8-Hydroxyrebamipide and 6-Hydroxyrebamipide.

来源:NORMAN Suspect List Exchange

反应信息

• 作为产物：
  描述：

  methyl 2-amino-3-<2(1H)-quinolinon-4-yl>propionate, salt with D-(-)-mandelic acid 在 盐酸 、 potassium carbonate 、 methyloxirane 作用下， 以 水 、 丙酮 为溶剂， 反应 7.5h， 生成 (R)-2-(4-氯苯甲酰胺基)-3-(1,2-二氢-2-氧代-4-喹啉基)丙酸
  参考文献：
  名称：

  2-（4-氯苯甲酰基氨基）-3- [2（1H）-喹啉酮-4-基]丙酸（瑞巴派特）的旋光异构体的合成和抗溃疡活性。

  摘要：

  2-（4-氯苯甲酰基氨基）-3- [2（1H）-喹啉酮-4-基]丙酸[（+/-）-1，瑞巴派特，OPC-12759]的对映异构体，一种增强粘膜的新型抗溃疡药由2（1H）-喹啉酮的旋光性α-氨基酸衍生物合成抗性。通过不对称合成和光学拆分制备了关键中间体α-氨基酸衍生物。（+）-1对乙醇诱导的胃溃疡的抗溃疡活性约为（-）-异构体的1.7倍。

  DOI：

  10.1248/cpb.39.2906

文献信息

• Micelle for solubilizing a sparingly water-soluble ingredient and solution comprising the same
  申请人：TEIKA PHARMACEUTICAL CO., LTD.

  公开号：US11318095B2

  公开（公告）日：2022-05-03

  The present invention provides a micelle comprising an anionic micelle and a protecting agent surrounding the anionic micelle, the anionic micelle being formed from, as a structural unit, an ingredient that has a functional group capable of being anionized under basic conditions and has anionic micelle-forming ability, the protecting agent protecting the anionic micelle. The present invention also provides a micelle comprising a cationic micelle and a protecting agent surrounding the cationic micelle, the cationic micelle being formed from, as a structural unit, an ingredient that has a functional group capable of being cationized under acidic conditions and has cationic micelle-forming ability, the protecting agent protecting the cationic micelle.

  本发明提供了一种胶束，包括一个阴离子胶束和围绕在阴离子胶束周围的保护剂，阴离子胶束是由具有在碱性条件下能被阴离子化的官能团并具有形成阴离子胶束能力的成分作为结构单元形成的，保护剂保护阴离子胶束。本发明还提供了一种胶束，包括阳离子胶束和围绕阳离子胶束的保护剂，阳离子胶束由具有在酸性条件下可被阳离子化的官能团并具有阳离子胶束形成能力的成分作为结构单元形成，保护剂保护阳离子胶束。
• MICELLE FOR SOLUBILIZING A SPARINGLY WATER-SOLUBLE INGREDIENT AND SOLUTION COMPRISING THE SAME
  申请人：TEIKA PHARMACEUTICAL CO., LTD.

  公开号：US20210137836A1

  公开（公告）日：2021-05-13

  The present invention provides a micelle comprising an anionic micelle and a protecting agent surrounding the anionic micelle, the anionic micelle being formed from, as a structural unit, an ingredient that has a functional group capable of being anionized under basic conditions and has anionic micelle-forming ability, the protecting agent protecting the anionic micelle. The present invention also provides a micelle comprising a cationic micelle and a protecting agent surrounding the cationic micelle, the cationic micelle being formed from, as a structural unit, an ingredient that has a functional group capable of being cationized under acidic conditions and has cationic micelle-forming ability, the protecting agent protecting the cationic micelle.